Mayes Patrick A sold $274K of INCY
Mayes Patrick A (EVP & Chief Scientific Officer) sold 2,207 shares of INCYTE CORP (INCY) at $123.99 ($0.27M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only new information is the specific insider sale size, price, and post-transaction holdings; it does not include any new corporate event.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates make it low-impact.
What to watch
The filing does not disclose any change in company guidance, trial results, or deal activity, so traders should avoid extrapolating it into fundamental conclusions.
Background
The article is an SEC Form 4 insider transaction disclosure for Incyte, reported from SEC EDGAR.
Ticker impact
Incyte Form 4 shows EVP and Chief Scientific Officer Mayes Patrick A sold 2,207 shares at $123.99 on 2026-08-05 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely short-lived and sentiment-driven.
The filing is a disclosed open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific operational or financial information.
Market effects
Minimal; insider sale does not change biotech sector fundamentals or regulatory/clinical expectations.
None.
None.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity management rather than bearish expectations.
Key entities
- issuerINCY
Incyte Corp, the company whose insider transaction is disclosed.
- insiderMayes Patrick A
EVP and Chief Scientific Officer who executed the open-market sale.
